<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04196803</url>
  </required_header>
  <id_info>
    <org_study_id>100106c</org_study_id>
    <nct_id>NCT04196803</nct_id>
  </id_info>
  <brief_title>Methylomic Biomarkers for Magnesium Deficiency in the Personalized Prevention of Colorectal Cancer Trial</brief_title>
  <official_title>Methylomic Biomarkers for Magnesium Deficiency and Colon Neoplasia Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on the magnesium (Mg) tolerance test, the &quot;gold standard&quot; test of Mg status, more than
      50% US participants had Mg deficiency. Observations suggest that the associations between
      high Mg intake and disease risks may completely differ by the underlying Mg status. Due to
      major limitations, the Mg tolerance test is not used in conventional clinical practice and
      rarely used in research. Instead, serum Mg is used for clinical diagnosis. However, serum Mg
      performs very poorly at identifying those with Mg deficiency. There is a great need to
      develop implementable, sensitive, and specific biomarkers which can be easily used for
      identifying people with Mg deficiency.

      It is known that DNA methylation changes are inducible by environmental exposures, including
      nutrients, and reversible when the exposure disappears. We propose to identify 5-hmC/5-mC
      biomarkers for Mg deficiency by a 4- phase EWAS study in the &quot;Personalized Prevention of
      Colorectal Cancer Trial [PPCCT, R01CA149633; PI, Dai &amp; Yu]&quot; with a total of 240 participants.
      Mg tolerance test will be used as the gold standard. Finally, using newly identified
      biomarkers, we will evaluate if 12-week Mg treatment reduces TRPM7 expression, essential in
      Mg homeostasis and colorectal carcinogenesis, in rectal tissues only among those with Mg
      deficiency.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2016</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5-mC and 5-hmC assays</measure>
    <time_frame>12 Weeks</time_frame>
    <description>DNA was extract from WBC samples and measured by using TAB-Seq &amp; TAB-Array protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum magnesium</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma methionine cycle metabolites</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Plasma SAM, SAH, homocysteine and methionine measured by stable-isotope dilution liquid chromatography-electrospray tandem mass spectrometry (LC-ESI-MS/MS)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>GG genotype and magnesium treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who have the GG genotype will be assigned to magnesium glycinate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GG genotype and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants who have the GG genotype will be assigned to placebo group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GA/AA genotype and magnesium treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who have the GA/AA genotype will be assigned to magnesium glycinate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GA/AA genotype and Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants who have the GA/AA genotype will be assigned to placebo group</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Magnesium glycinate</intervention_name>
    <description>Oral administration of magnesium glycinate daily for 12 weeks</description>
    <arm_group_label>GA/AA genotype and magnesium treatment</arm_group_label>
    <arm_group_label>GG genotype and magnesium treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration of identical-appearing placebo daily for 12 weeks</description>
    <arm_group_label>GA/AA genotype and Placebo</arm_group_label>
    <arm_group_label>GG genotype and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants from our parent study (Personalized Prevention of Colorectal Cancer
             Trial, NCT#01105169, IRB#100106);

          2. Participants consent to store/share biospecimens for future research.

        Exclusion Criteria:

        1. Participants cannot provide their blood samples in the parent study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Qi Dai</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Magnesium Deficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

